Transcript
Biosimilars And FollowOn Biologics Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client.
Research Capabilities
Sector Coverage
Customized Research Syndicated Research Investment Research Social Media Research
Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment
Customized Research
Subscription Information
Syndicated Research
For detailed subscription information please contact
Investment Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media Research
Hari. T (Sr. Manager - Global Business Development)
Email:
[email protected]
Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas
Report Description Report Description Biosimilars is defined as a type of biological product that is similar to another drug, which has already been licensed (approved) by the US FDA or European Medicines Agency. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. These drugs are also coined as follow-on biologics and are mostly derived from biological sources such as bacterium and yeast. The constitution of the biosimilar drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biosimilars are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biosimilars can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. A good example for this is Pfizer acquisition of Hospira, to gain access to the latter’s attractive biosimilars portfolio. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biosimilar drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years. Biosimilars and Follow-on Biologics Market: Drivers and Restraints Drivers for the biosimilars market include big brand name drugs losing patent extensions, cuts in healthcare costs across nations, forming of incentivized pricing policies by companies in order to access high growth pharmerging markets and good development in pharmacovigilance procedures across the globe. Other factors increasing the demand for biosimilar drugs include rising disease incidences across the globe and better access to healthcare for all nations.
Report Description Report Description Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1250 Restraints for the market include constraints in developing and registering biosimilar drugs and the complexity in the manufacturing processes. The drugs are difficult to verify and have to undergo complex regulations. Further, the drugs are different from each other due to variability in raw material and in the manufacturing process, which is expected to deter the future development of biosimilar drugs. There are also risks in having an increase in the versions of an identical biosimilar drug. Biosimilars and Follow-on Biologics Market: Segmentation Biosimilars and Follow-on Biologics Market can be segmented into these following ways: • Segmentation by product class • epoetins; • filgrastims; • insulins; • growth hormones; • alfa interferons;
Report Description Report Description • monoclonal antibodies; • beta interferons; • follitropins; • low-molecular-weight heparins (LMWH). • Segmentation by application
• Rheumatoid arthritis • Anemia • Cancer • Diabetes • Others • Segmentation by regions Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1250
Report Description Report Description Biosimilars and Follow-on Biologics Market: Overview Biosimilar market is expected to gain prominence over the forthcoming years due to leading biologic drugs expected to lose exclusivity over the next seven years. Further, biosimilar drugs, once formed, are expected to generate cost savings for the patient population. Competition is expected to be limited in the market as the drugs are expected to be formed using various types of innovative technologies. Biosimilars may generate smaller savings for drug makers because of their complexity as well as regulatory challenges of getting FDA approvals. Biosimilars and Follow-on Biologics Market: Region-wise Outlook Depending on geographic regions, biosimilar drug market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. In terms of geography, Europe dominates the market, followed by Asia-Pacific. However, rising technological advancement in healthcare and systematic drug review process will drive the markets over North America, Japan and other regions. Europe dominates the biosimilars market driven by technically advanced healthcare infrastructure and high patient awareness & regulatory harmonization. Increasing funding for development of biosimilar drugs, availability of high-quality research infrastructure and strategies developed by drug makers to restrict entry of new players. Emerging markets include Eastern European countries followed by countries in Eastern Africa.
Report Description Report Description Rising disease incidences in these countries is expected to prove favorable for the growth of the biosimilar drug market. Browse full report: http://www.futuremarketinsights.com/reports/biosimilars-andfollow-on-biologics-market Biosimilars and Follow-on Biologics Market: Key Players Some of the key players in biosimilar market are Pfizer Inc. (AC. Hospira), Sandoz International GmbH, , Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc. , Amgen, Celltrion Inc., Roche Diagnostics, and Merck KGaA.
Thank You!
To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on:
[email protected]
For other queries contact: Mr. Sudip Saha Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705
